Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5
January 29, 2025 08:00 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement
January 28, 2025 08:00 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
Calidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025
January 13, 2025 08:00 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock
January 10, 2025 16:30 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock
January 10, 2025 08:30 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
Calidi Biotherapeutics Announces Proposed Public Offering
January 08, 2025 16:01 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer
November 18, 2024 08:00 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock
November 15, 2024 16:05 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock
November 14, 2024 08:30 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
Calidi Biotherapeutics Announces Proposed Public Offering
November 13, 2024 16:33 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...